Want to see CSTL full AI Analyst Report?

Castle Biosciences (CSTL) Stock Forecast & Price Target

462 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CSTL Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Castle

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CSTL Stock 12 Month Forecast

Average Price Target

$42.14

▲(70.76% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Castle Biosciences in the last 3 months. The average price target is $42.14 with a high forecast of $57.00 and a low forecast of $35.00. The average price target represents a 70.76% change from the last price of $24.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","58":"$58","24.25":"$24.3","35.5":"$35.5","46.75":"$46.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.142857142857146,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,24.25,35.5,46.75,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.71,27.193846153846156,29.677692307692308,32.16153846153846,34.645384615384614,37.12923076923077,39.613076923076925,42.096923076923076,44.580769230769235,47.06461538461539,49.54846153846154,52.0323076923077,54.51615384615385,{"y":57,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.71,26.050989010989014,27.391978021978023,28.732967032967036,30.073956043956045,31.414945054945058,32.75593406593407,34.096923076923076,35.43791208791209,36.7789010989011,38.119890109890115,39.46087912087913,40.80186813186813,{"y":42.142857142857146,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.71,25.501538461538463,26.293076923076924,27.084615384615386,27.876153846153848,28.66769230769231,29.45923076923077,30.25076923076923,31.042307692307695,31.833846153846153,32.62538461538462,33.41692307692308,34.208461538461535,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.47,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.81,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.71,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$57.00

Average Price Target$42.14

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Catherine Ramsey Schulte

Robert W. Baird

$43→$36

Buy

45.87%

Upside

Reiterated

07/31/26

Castle Biosciences price target lowered to $36 from $43 at BairdCastle Biosciences price target lowered to $36 from $43 at Baird

Thomas Flaten

Lake Street

$52→$57

Buy

130.96%

Upside

Reiterated

07/31/26

Castle Biosciences price target raised to $57 from $52 at Lake StreetCastle Biosciences price target raised to $57 from $52 at Lake Street

Max Masucci

Roth MKM

$40

Buy

62.07%

Upside

Reiterated

07/31/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Knight

KeyBanc

$50→$35

Buy

41.82%

Upside

Reiterated

05/29/26

Castle Biosciences price target lowered to $35 from $50 at KeyBancCastle Biosciences price target lowered to $35 from $50 at KeyBanc

Mark Massaro

BTIG

$50→$40

Buy

62.07%

Upside

Reiterated

05/13/26

Castle Biosciences: Buy Reiterated on Strong Q1 Execution and Undervalued Growth Potential Despite Price Target Trim to $40

Subbu Nambi

Guggenheim

$47

Buy

90.44%

Upside

Reiterated

05/07/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)

Kyle Mikson CFA

Canaccord Genuity

$40

Buy

62.07%

Upside

Reiterated

05/06/26

Castle Biosciences: Buy Rating Reiterated as Strong Q1, Raised 2026 Outlook and Unchanged $40 Price Target Underscore Undervaluation

Puneet Souda

Leerink Partners

$35

Buy

41.82%

Upside

Reiterated

08/05/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Castle Biosciences (NASDAQ: CSTL) and Regeneron (NASDAQ: REGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Catherine Ramsey Schulte

Robert W. Baird

$43→$36

Buy

45.87%

Upside

Reiterated

07/31/26

Castle Biosciences price target lowered to $36 from $43 at BairdCastle Biosciences price target lowered to $36 from $43 at Baird

Thomas Flaten

Lake Street

$52→$57

Buy

130.96%

Upside

Reiterated

07/31/26

Castle Biosciences price target raised to $57 from $52 at Lake StreetCastle Biosciences price target raised to $57 from $52 at Lake Street

Max Masucci

Roth MKM

$40

Buy

62.07%

Upside

Reiterated

07/31/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Knight

KeyBanc

$50→$35

Buy

41.82%

Upside

Reiterated

05/29/26

Castle Biosciences price target lowered to $35 from $50 at KeyBancCastle Biosciences price target lowered to $35 from $50 at KeyBanc

Mark Massaro

BTIG

$50→$40

Buy

62.07%

Upside

Reiterated

05/13/26

Castle Biosciences: Buy Reiterated on Strong Q1 Execution and Undervalued Growth Potential Despite Price Target Trim to $40

Subbu Nambi

Guggenheim

$47

Buy

90.44%

Upside

Reiterated

05/07/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)

Kyle Mikson CFA

Canaccord Genuity

$40

Buy

62.07%

Upside

Reiterated

05/06/26

Castle Biosciences: Buy Rating Reiterated as Strong Q1, Raised 2026 Outlook and Unchanged $40 Price Target Underscore Undervaluation

Puneet Souda

Leerink Partners

$35

Buy

41.82%

Upside

Reiterated

08/05/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Castle Biosciences (NASDAQ: CSTL) and Regeneron (NASDAQ: REGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Castle Biosciences

3 Months

Max MasucciRoth MKM

Success Rate

11/15 ratings generated profit

Average Return

+16.91%

Copying Max Masucci's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +16.91% per trade.

1 Year

Thomas FlatenLake Street

Success Rate

14/23 ratings generated profit

Average Return

+7.27%

Copying Thomas Flaten's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +7.27% per trade.

2 Years

Kyle Mikson CFACanaccord Genuity

Success Rate

16/26 ratings generated profit

Average Return

+10.10%

Copying Kyle Mikson CFA's trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of +10.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CSTL Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CSTL has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CSTL average Analyst price target in the past 3 months is 42.14.

Each month's total comprises the sum of three months' worth of ratings.

CSTL Financial Forecast

CSTL Earnings Forecast

The previous quarter’s earnings for CSTL were -$0.07.

CSTL Sales Forecast

The previous quarter’s earnings for CSTL were $103.55M.

CSTL Stock Forecast FAQ

What is CSTL’s average 12-month price target, according to analysts?

Based on analyst ratings, Castle Biosciences’s 12-month average price target is 42.14.

What is CSTL’s upside potential, based on the analysts’ average price target?

Castle Biosciences has 70.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CSTL a Buy, Sell or Hold?

Castle Biosciences has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Castle Biosciences’s price target?

The average price target for Castle Biosciences is 42.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $57.00 ,the lowest forecast is $35.00. The average price target represents 70.76% Increase from the current price of $24.68.

What do analysts say about Castle Biosciences?

Castle Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of CSTL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Castle Biosciences (CSTL) Stock Forecast & Price Target

CSTL Analyst Ratings

CSTL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Castle Biosciences

CSTL Analyst Recommendation Trends

CSTL Financial Forecast

CSTL Earnings Forecast

CSTL Sales Forecast

CSTL Stock Forecast FAQ

Detailed List of Analyst Forecasts